P-55: Protection Role of GnRH Antagonist (Cetrorelix) on Cisplatin Infertility Side Effect

Background: Infertility problem affects 20-30% of young couples. One of the known causes of spermatogenesis disorder is chemotherapy in patients with cancer which its side effect may last up to the end of the life. Since dividing cells are mainly affected by anticancer drugs, the aim of the present study is to investigate the preventive effect of GnRH on spermatogenic defect produced by anticancer drugs. Materials and Methods: In the present study adult male mice aging 6-8 weeks were divided into 3 groups as:control, cisplatin(cis group) and cisplatin+cetrorelix(cis,cetro group). Cisplatin was injected single dose (2.5 mg/kg) for 5 days intraperitoneally. Cis+cetro group received cetrorelix one week before cisplatin treatment and continued for 3 weeks. The mice in all groups were sacrificed 35 days after cisplatin injection and testis specimens were prepared for Light Microscopic studies. Results: LM study showed that mean diameter of seminiferous tubules in control group was 57.33 ± 4.1µm, in cis group 20.90 ± 3.84 µm and in cis+cetro group was 50.09 ± 4.08µm .The rate of spermatogonia in control group was 43.22 ± 1.55, in cis group was 21.43 ± 2.44 and in cis +cetro was 40.53 ± 2038.The rate of setoli cells in control group was 5.50 ± 0.52, in cis group was 8.61 ± 0.80 and in cis +cetro was 5.09 ± 0.96. The rate of spermyogenesis Index (SI) in control group was 23.00 ± 10.67 and in cis group was 1.52 ± 1.39 and in cis +cetro was 5.71 ± 8.80. Statistical analysis of data showed significant differences in rate of spermatogonia, sertoli, SI and thickness of seminiferous tubules between control and cisplatin group (p<0.05). Conclusion: It is concluded that GnRH antagonist administration before cancer treatment could prevent the infertility side effect of cisplatin anticancer drug.